Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro™/GentleMax Pro Plus™

Candela Corporation

Status

Active, not recruiting

Conditions

Unwanted Fine Facial Hair

Treatments

Device: GentleMax Pro Plus 755nm and 1064nm laser system

Study type

Interventional

Funder types

Industry

Identifiers

NCT04975243

GMP20001

Details and patient eligibility

About

This clinical study is intended to evaluate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended use of hair removal while using short pulse durations to improve the efficacy of achieving permanent reduction of fine facial hairs.

Full description

Prospective, non-randomized, open label trial to evaluate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended use of hair removal with variable pulse durations and spot sizes.

Up to 30 subjects may be enrolled in this study at one (1) investigational site. Subjects having difficult to treat unwanted fine facial hairs having Fitzpatrick skin type (FST) I to VI are eligible for this study.

In order to have a diverse sample of study subjects, the following criteria was established to ensure a wide array of skin types and race and ethnicities for data analysis. At least 15 subjects must have FST III to V. The remaining subjects can include other FST, but must still have fine facial hairs where permanent hair reduction is difficult to achieve with 3 ms pulses.

Participants will receive four (4) laser hair removal treatment visits (with maximum interval of 10 weeks in between treatment visits) depending on the treatment area and three (3) follow up visits (1 month, 3 month, and 6 month after final treatment).

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

At least 18 years of age or older
Willingness to provide signed, informed consent to participate in the study
Presence of unwanted hair of desired characteristics and treatment location to be evaluated in this study
Willingness to adhere to study treatment and follow-up schedule
Willingness to adhere to post-treatment care instructions
Willingness to allow photographs and/or video of treated areas, and to release their use for scientific/educational and/or promotional/marketing purposes
Willing to abstain from any other procedures, medications or topicals in the study treatment areas for the duration of the study which the investigator deems would interfere with the study

Exclusion criteria

Pregnant, planning pregnancy during the study, or breast feeding
Blonde, grey, or white hair in subjects seeking hair removal
Tattooed skin in the intended treatment area
Active suntan in the intended treatment area
History of active Herpes Virus Simplex (HSV) or similar condition in the intended treatment area unless treated with prophylactic medication
History of melanoma
History of vitiligo in the intended treatment area
History of keloid or hypertrophic scar formation
History of Melasma in the intended treatment area or per Investigator's discretion
Severe immunosuppression resulting from medications and/or a medical condition that could impair healing after treatment
Open wound or infection in the intended treatment area
History of light induced seizure disorders
The subject is not suitable, in the opinion of the Investigator, for participation in the study due to inability to adhere to the study requirements, medical, or other reasons that could compromise the study integrity or subject safety
Dermatologic and/or cosmetic procedures including use of medications, or topicals in the intended treatment area(s) during a timepoint prior to the study that the investigator deems the subject unsuitable for the study